Citius Pharma reports Q1 net loss of $3.6M ($0.02/sh); cash runway through Feb 2024

Citius Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.02

Net loss of $3.6M ($0.02 EPS) improved from $9.2M ($0.06 EPS) in Q1 2022.
Cash and equivalents $36.9M; runway expected to fund operations through Feb 2024.
I/ONTAK BLA under FDA review with PDUFA target date July 28, 2023.
Mino-Lok Phase 3 trial expanding; enrollment uptick in U.S. and India.
Director Dennis McGrath elected, replacing Dr. William Kane.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.87

Citius Pharmaceuticals, Inc. reported the fiscal first quarter ended December 31, 2022 results: net income Net loss was $3.6 million, or ($0.02) per share, EPS $0.02.

Period: the fiscal first quarter ended December 31, 2022
Net income: Net loss was $3.6 million, or ($0.02) per share
EPS: $0.02
Result: reported results

Exact text from the filing

On February 10, 2023, we issued a press release announcing our results of operations for the first quarter of fiscal 2023.

View on SEC.gov

Browse all earnings releases →

Citius Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-010323

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.